X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs PANACEA BIOTECH - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD PANACEA BIOTECH LUPIN LTD/
PANACEA BIOTECH
 
P/E (TTM) x 22.9 155.1 14.8% View Chart
P/BV x 3.1 3.4 90.2% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 LUPIN LTD   PANACEA BIOTECH
EQUITY SHARE DATA
    LUPIN LTD
Mar-17
PANACEA BIOTECH
Mar-14
LUPIN LTD/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,750149 1,176.9%   
Low Rs1,38482 1,681.0%   
Sales per share (Unadj.) Rs387.484.1 460.4%  
Earnings per share (Unadj.) Rs56.6-18.3 -309.4%  
Cash flow per share (Unadj.) Rs76.8-6.7 -1,147.0%  
Dividends per share (Unadj.) Rs7.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs298.983.7 357.1%  
Shares outstanding (eoy) m451.5861.25 737.3%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x4.01.4 294.6%   
Avg P/E ratio x27.7-6.3 -438.5%  
P/CF ratio (eoy) x20.4-17.2 -118.3%  
Price / Book Value ratio x5.21.4 379.9%  
Dividend payout %13.20-   
Avg Mkt Cap Rs m707,5137,074 10,001.1%   
No. of employees `00016.82.8 610.6%   
Total wages/salary Rs m28,4951,449 1,966.3%   
Avg. sales/employee Rs Th10,418.31,874.1 555.9%   
Avg. wages/employee Rs Th1,697.0527.0 322.0%   
Avg. net profit/employee Rs Th1,523.0-407.7 -373.5%   
INCOME DATA
Net Sales Rs m174,9435,154 3,394.5%  
Other income Rs m1,065100 1,067.2%   
Total revenues Rs m176,0085,254 3,350.3%   
Gross profit Rs m44,931-766 -5,863.4%  
Depreciation Rs m9,122711 1,283.0%   
Interest Rs m1,5251,503 101.5%   
Profit before tax Rs m35,349-2,881 -1,227.2%   
Minority Interest Rs m-7211 -663.9%   
Prior Period Items Rs m83-6 -1,447.4%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m9,78517 58,244.6%   
Profit after tax Rs m25,575-1,121 -2,280.8%  
Gross profit margin %25.7-14.9 -172.7%  
Effective tax rate %27.7-0.6 -4,746.2%   
Net profit margin %14.6-21.8 -67.2%  
BALANCE SHEET DATA
Current assets Rs m119,5423,810 3,137.4%   
Current liabilities Rs m61,2068,365 731.7%   
Net working cap to sales %33.3-88.4 -37.7%  
Current ratio x2.00.5 428.8%  
Inventory Days Days76156 48.8%  
Debtors Days Days9067 133.7%  
Net fixed assets Rs m131,66014,480 909.2%   
Share capital Rs m90361 1,473.4%   
"Free" reserves Rs m134,073903 14,845.8%   
Net worth Rs m134,9765,127 2,632.5%   
Long term debt Rs m56,4785,832 968.5%   
Total assets Rs m266,07319,433 1,369.2%  
Interest coverage x24.2-0.9 -2,637.8%   
Debt to equity ratio x0.41.1 36.8%  
Sales to assets ratio x0.70.3 247.9%   
Return on assets %10.22.0 518.6%  
Return on equity %18.9-21.9 -86.6%  
Return on capital %19.33.6 529.8%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m81,8851,539 5,319.9%   
Fx outflow Rs m21,506942 2,283.0%   
Net fx Rs m60,378597 10,110.2%   
CASH FLOW
From Operations Rs m41,148599 6,867.1%  
From Investments Rs m-25,287-438 5,774.6%  
From Financial Activity Rs m4,332-303 -1,431.5%  
Net Cashflow Rs m20,193-141 -14,290.5%  

Share Holding

Indian Promoters % 46.6 74.5 62.6%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 0.6 1,883.3%  
FIIs % 31.9 1.3 2,453.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 23.6 42.8%  
Shareholders   98,259 10,259 957.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare LUPIN LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jan 22, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS